Clinical trials: Advanced Digestive System Tumor
Carcinoma, Hepatocellular
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer.
- Trial name
- NCT00699374
- Testing
- sunitinib malate, sorafenib
- Where
- 171 sites in United States, Australia and 21 more
- Volunteers
- 1,075 people
- Sponsor
- Pfizer
Gastric Cancer
Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
This open-label, single-arm, multicenter, Phase 2 trial will treat at least 40 participants with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction (GEJ) who have not previously received…
- Trial name
- NCT01388790
- Testing
- Cetuximab, Cisplatin, S-1
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Gastric Adenocarcinoma
Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The primary objective of this study is to compare the efficacy of andecaliximab (GS-5745) versus placebo in combination with modified fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (OXA) (mFOLFOX6) as measured by overall…
- Trial name
- GAMMA-1 (NCT02545504)
- Testing
- Andecaliximab, Leucovorin, 5-fluorouracil
- Where
- 134 sites in United States, Australia and 14 more
- Volunteers
- 432 people
- Sponsor
- Gilead Sciences
Pancreatic Neoplasms
Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer.
- Trial name
- LAPACT (NCT02301143)
- Testing
- nab-Paclitaxel, Gemcitabine, Chemoradiation
- Where
- 42 sites in United States, Canada and 3 more
- Volunteers
- 107 people
- Sponsor
- Celgene
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
This phase II trial studies the best dose and side effects of sorafenib tosylate and nivolumab in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to nearby tissues or lymph nodes…
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT03439891
- Testing
- Nivolumab, Sorafenib
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Robin Kate Kelley
Colorectal Cancer
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
The standard or usual treatment for this disease is treatment with drugs and other treatments that may help to make a patient better or may improve their quality of life. This treatment is known as "best supportive care" (BSC).
- Trial name
- NCT02870920
- Testing
- Tremelimumab, Durvalumab, Best Supportive Care
- Where
- 25 sites in Canada
- Volunteers
- 180 people
- Sponsor
- Canadian Cancer Trials Group
Advanced Solid Tumors, Hepatocellular Carcinoma
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
This is a two-part trial. "Solid tumor" in this protocol means solid tumor excluding hepatocellular carcinoma (HCC). Part 1: Dose Escalation Phase in subjects with solid tumor (Cohort A) and HCC (Cohort B).
- Trial name
- NCT01668017
- Testing
- Pimasertib
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hepatocellular Carcinoma
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy and safety of Nofazinlimab (CS1003) in combination with lenvatinib and placebo in combination with lenvatinib in the treatment of…
- Trial name
- NCT04194775
- Testing
- Nofazinlimab (CS1003)+Lenvatinib
- Where
- 74 sites in United States, China and 4 more
- Volunteers
- 534 people
- Sponsor
- CStone Pharmaceuticals
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive…
- Trial name
- NCT03615326
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 192 sites in United States, Australia and 18 more
- Volunteers
- 738 people
- Sponsor
- Merck Sharp & Dohme LLC
Well-differentiated Pancreatic Neuroendocrine Tumor
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.
- Trial name
- NCT01525550
- Testing
- sunitinib
- Where
- 26 sites in United States, Australia and 13 more
- Volunteers
- 106 people
- Sponsor
- Pfizer
Neoplasms
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression.
- Trial name
- NCT02659631
- Testing
- PF-06671008
- Where
- 9 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, Colorectal Cancer
Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
The purpose of this study is to find out if dovitinib is an effective treatment for patients with advanced lung cancer or advanced colorectal cancer (CRC) who have progressed on anti-vascular endothelial growth factor (VEGF)…
- Trial name
- NCT01676714
- Testing
- Dovitinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Davis
Islet Cell Tumor
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
This study will estimate the treatment effect of everolimus in combination with pasireotide LAR relative to everolimus alone on progression-free survival (PFS) in patients with advanced progressive PNET.
- Trial name
- COOPERATE-2 (NCT01374451)
- Testing
- Everolimus, Pasireotide LAR
- Where
- 47 sites in United States, Argentina and 17 more
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body.
- Conditions
- Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
- Trial name
- NCT03910387
- Testing
- Gemcitabine, Nab-paclitaxel, Telotristat Ethyl
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Emory University
Pancreatic Cancer
Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either…
- Trial name
- NCT00310050
- Testing
- pemetrexed disodium, Radiotherapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Solid Tumor, Colorectal Cancer
Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall…
- Trial name
- NCT02953782
- Testing
- Magrolimab, Cetuximab
- Where
- 8 sites in United States
- Volunteers
- 78 people
- Sponsor
- Gilead Sciences
Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell
Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
The purpose of this registry is to obtain a general view as regards efficacy, tolerability and safety issues of the Torisel®, Sutent®, and/or Inlyta® therapies in patients with advanced renal cell carcinoma, recurrent /…
- Conditions
- Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
- Trial name
- STAR-TOR (NCT00700258)
- Testing
- Temsirolimus, Sunitinib, Axitinib
- Where
- 77 sites in Germany
- Volunteers
- 1,520 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Non-small Cell Lung Cancer
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2…
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04442126
- Testing
- NM21-1480
- Where
- 26 sites in United States, Spain and 1 more
- Volunteers
- 52 people
- Sponsor
- Numab Therapeutics AG
Esophageal Cancer
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer
Esophageal cancer is a highly aggressive tumor. Treatment options are various and range from chemotherapy to radiotherapy and several surgical techniques. Nevertheless, the overall survival rates for this disease remain poor.
- Trial name
- NCT01787006
- Testing
- Cetuximab, Cisplatin, 5-FU, Radiotherapy
- Where
- Germany
- Volunteers
- 74 people
- Sponsor
- University Hospital Schleswig-Holstein